Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBP NASDAQ:CING NASDAQ:FRTX NASDAQ:PMN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.41-3.1%$0.43$0.22▼$15.80$20.40M0.839.34 million shs881,859 shsCINGCingulate$3.91-1.0%$4.46$3.02▼$6.01$21.15M-0.76142,162 shs61,048 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsPMNPromis Neurosciences$0.42-4.9%$0.59$0.38▼$1.59$21.68M-0.052.89 million shs568,199 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma0.00%-16.96%+18.41%+20.46%+42,509,900.00%CINGCingulate0.00%+1.28%-2.23%-12.42%-26.85%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+26.35%PMNPromis Neurosciences0.00%+2.30%-28.70%-13.58%-64.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.41-3.1%$0.43$0.22▼$15.80$20.40M0.839.34 million shs881,859 shsCINGCingulate$3.91-1.0%$4.46$3.02▼$6.01$21.15M-0.76142,162 shs61,048 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsPMNPromis Neurosciences$0.42-4.9%$0.59$0.38▼$1.59$21.68M-0.052.89 million shs568,199 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma0.00%-16.96%+18.41%+20.46%+42,509,900.00%CINGCingulate0.00%+1.28%-2.23%-12.42%-26.85%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+26.35%PMNPromis Neurosciences0.00%+2.30%-28.70%-13.58%-64.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/ACINGCingulate 3.00Buy$26.25571.36% UpsideFRTXFresh Tracks Therapeutics 0.00N/AN/AN/APMNPromis Neurosciences 3.00Buy$4.33935.69% UpsideCurrent Analyst Ratings BreakdownLatest FRTX, ASBP, CING, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.008/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/21/2025PMNPromis NeurosciencesLeede FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy7/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.007/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/ACINGCingulateN/AN/AN/AN/A$2.32 per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56PMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-737.96%N/ACINGCingulate-$15.55M-$4.10N/AN/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)FRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/APMNPromis Neurosciences$2.78M-$0.21N/AN/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)Latest FRTX, ASBP, CING, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/A8/13/2025Q2 2025ASBPAspire BiopharmaN/A-$0.04N/A-$0.04N/AN/A8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.090.09CINGCingulateN/A1.521.52FRTXFresh Tracks TherapeuticsN/AN/AN/APMNPromis NeurosciencesN/A0.970.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%CINGCingulate41.31%FRTXFresh Tracks Therapeutics25.04%PMNPromis Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%CINGCingulate4.04%FRTXFresh Tracks Therapeutics0.23%PMNPromis Neurosciences6.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/ACINGCingulate205.41 million5.19 millionNot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionablePMNPromis Neurosciences551.81 million48.64 millionNot OptionableFRTX, ASBP, CING, and PMN HeadlinesRecent News About These CompaniesProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310September 3, 2025 | globenewswire.comProMIS Neurosciences reports Q2 EPS (29c) vs (13c) last yearAugust 13, 2025 | msn.comProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate HighlightsAugust 13, 2025 | globenewswire.comProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International ConferenceJuly 29, 2025 | globenewswire.comProMIS Neurosciences Announces Private Placement FinancingJuly 28, 2025 | globenewswire.comProMIS Neurosciences Announces Private Placement FinancingJuly 22, 2025 | globenewswire.comProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's DiseaseJuly 21, 2025 | globenewswire.comProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's DiseaseJuly 21, 2025 | globenewswire.comHC Wainwright & Co. Initiates Coverage of ProMIS Neurosciences (PMN) with Buy RecommendationJuly 15, 2025 | msn.comProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 17, 2025 | globenewswire.comProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's DiseaseMay 13, 2025 | nasdaq.comProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | BenzingaMay 13, 2025 | benzinga.comProMIS Neurosciences Announces First Quarter 2025 Financial ResultsMay 12, 2025 | globenewswire.comProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last yearMarch 31, 2025 | markets.businessinsider.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International ConferenceMarch 24, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual MeetingMarch 13, 2025 | globenewswire.comProMIS Neurosciences to Participate in the 37th Annual Roth ConferenceMarch 11, 2025 | globenewswire.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s DiseaseFebruary 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Costco and Ross: 2 Ways to Play the Consumer DivideBy Chris Markoch | August 24, 2025Williams-Sonoma Q2 Results Prove Its Buy-and-Hold QualityBy Thomas Hughes | August 27, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025FRTX, ASBP, CING, and PMN Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.41 -0.01 (-3.11%) As of 04:00 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Cingulate NASDAQ:CING$3.92 -0.03 (-0.86%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Fresh Tracks Therapeutics NASDAQ:FRTXFresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Promis Neurosciences NASDAQ:PMN$0.42 -0.02 (-4.89%) Closing price 04:00 PM EasternExtended Trading$0.43 +0.01 (+2.53%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
